银杏内酯注射液联合依达拉奉治疗急性脑梗死的疗效及机制研究

Effect and mechanism of ginkgolide injection combined with edaravone on acute cerebral infarction

目的探讨银杏内酯注射液联合依达拉奉治疗急性脑梗死的疗效及机制。方法选取120例急性脑梗死患者，采用随机数字表法分为观察组和对照组，每组60例。对照组给予依达拉奉治疗，观察组给予银杏内酯注射液联合依达拉奉治疗。比较两组血清神经元特异性烯醇化酶（NSE）、S100β、肿瘤坏死因子α（TNF-α）、白细胞介素6（IL-6）及C反应蛋白（GriP）水平；比较两组美国国立卫生研究院卒中量表（NIHSS）评分及临床疗效。结果治疗后，观察组血清NSE、S100β、CRP、IL-6、TNF-α分别为（7．1±1．5）μg/L、（O．2±0．1）μg/L、（14．5±3．7）mg／L、（20．9±5．3）ng／L、（11．2±3．0）μg/L，对照组分别为（8．9±2．0）μg/L、（0．4±0．2）μg/／L、（21．3±4．2）mg／L、（29．7±3．2）ng／L、（18．8±3．6）μg/L，观察组均显著低于对照组（t=2．898、2．894、3．012、2．998、3．025，均P〈0．05）。治疗后7d、14d，观察组NIHSS评分分别为（11．8±3．0）分、（7．3±2．2）分，对照组分别为（15．2±3．9）分、（10．5±3．O）分，观察组均显著低于对照组（t=2．984、3．037，P〈0．05）。观察组总有效率显著高于对照组（83．3％比61．7％）（x^2=7．064，P〈0．05）。结论银杏内酯注射液联合依达拉奉治疗急性脑梗死，可抑制炎性反应，减轻神经功能损伤，其效果优于单纯依达拉奉治疗。

Objective To evaluate the effect and mechanism of ginkgolide injection combined with edaravone on acute cerebral infarction. Methods 120 acute cerebral infarction patients were divided into observation group and control group,60 eases in each group. The control group was treated with edaravone, and the observation group was treated with ginkgolide injection combined with edaravone. The neuron specific enolase （ NSE ）, S100β, tumor necrosis factor - α （ TNF - α）, interleukin - 6 （ IL - 6 ）, C reactive protein （ CRP ）, National Institutes of Health stroke scale（ N[HSS ） and clinical efficacy were compared between the two groups. Results After treatment, the levels of NSE, S100β, CRP, IL - 6 and TNF -α of the observation group were （7.1 ± 1.5 ） μg/L, （ 0.2 ± 0.1 ） μg/L,（ 14.5 ± 3.7） mg/L, （20.9 ± 5.3） ng/L and （ 11.2 ± 3.0） μg/L, respectively, which of the control group were （ 8.9 ± 2.0） μg/L, （0.4 ± 0.2） μg/L, （21.3 ± 4.2） mg/L, （29.7 ± 3.2 ） ng/L and （ 18.8 ± 3.6 ） μg/L, respectively, those of the observation group were significantly lower than control group（ t = 2. 898,2. 894,3. 012,2. 998,3. 025, all P 〈 0. 05 ）. After treatment for 7d and 14d,the NIHSS scores of the observation group were （ 11.8 ± 3.0） points and （7.3 ± 2.2） points ,respectively,which of the control group were （15.2 ± 3.9）points and （10.5 ± 3.0 ）points, respectively, the observation group were significantly lower than control group （t = 2.984,3. 037, all P 〈 0.05 ）. The clinical efficacy of the observation group was significantly better than that of the control group（ 83.3% vs. 61.7% ） （ X^2 = 7. 064 ,P 〈 0.05）. Conclusion Ginkgolide injection combined with edaravone in the treatment of acute cerebral infarction can inhibit inflammation reaction,alleviate nerve function damage,its effect is better than edaravone.